Authors

Latest:

Yong-Chen William Lu on Adoptive T-Cell Therapy in Solid Tumors

Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.

You-cai Zhu, MD, PhD

Latest:

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC

You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Young Kwang Chae, MD, MPH, MBA

Latest:

Dr. Chae on Using Crizotinib to Treat MET+ NSCLC

Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.

Yu (Amy) Zong

Latest:

Nab-Paclitaxel as Neoadjuvant Therapy for Breast Cancer

Yu (Amy) Zong, Shanghai Jiaotong University School of Medicine, discusses a meta-analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as neoadjuvant chemotherapy of breast cancer.

Yubin Kang, MD

Latest:

Dr. Kang on the Preclinical Activity of ABC294640 in Multiple Myeloma

Yubin Kang, MD, a professor of medicine and member of Duke Cancer Institute, discusses the preclinical activity of the SK-2 inhibitor ABC294640 in multiple myeloma.

Yue Xiong, PhD

Latest:

5 questions with Yue Xiong

The beat on the people, devices, trends, and companies shaping healthcare... with Yue Xiong, PhD, Professor of Biochemistry and Biophysics, UNC Lineberger Comprehensive Cancer Center.

Yujin Hoshida, MD, PhD

Latest:

Dr. Hoshida on Molecular Subtyping in HCC

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

Yung-Jue Bang, MD, PhD

Latest:

Dr. Bang on Pembrolizumab for Advanced Gastric Cancer

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

Yuqin Song, MD, PhD

Latest:

Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCL

Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.

Yuri E. Nikiforov, MD, PhD

Latest:

Dr. Nikiforov on Reclassifying Subtype of Thyroid Cancer

Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Yvonne Lin, MD, MS

Latest:

Immunotherapy Examined as Treatment Option in Locally Advanced Cervical Cancer

The notion of commandeering the immune system to treat cancer actually dates back more than a century with intratumoral bacterial injections to try and elicit tumor regression.

Yvonne M. Saenger, MD

Latest:

Dr. Saenger on the Need for Immunotherapy Biomarkers

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

Yvonne N. Fondufe-Mittendorf, PhD

Latest:

University of Kentucky Lab Seeks to Decode Epigenetic Signals in Cancer

Although many labs study cancer as an all-or-nothing process, putting all metastable hybrid stages in the same bin, our laboratory at the University of Kentucky is exploring carcinogenesis as a continuum, from initiation through progression to maintenance. This approach has prompted us to focus on the role of epigenetics in cancer development.

Yvonne Saenger, MD

Latest:

Dr. Saenger on Immunotherapy Combinations in Melanoma

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.

Yvonne Weideman, DNP, MBA, RN, CNE

Latest:

Matching Ostomy Pouching Systems to Patient Need

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

Zachariah DeFilipp, MD

Latest:

Safety and Efficacy of Axatilimab in Patients With Chronic Graft-Versus-Host Disease (AGAVE-201)

Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).

Zachariah M. DeFilipp, MD, Massachusetts General Hospital

Latest:

Updates in the Management of Graft-Versus-Host Disease

Zachary C. Landman, MD

Latest:

Dr. Landman on Delivering Value-Based Care to Patients

Zachary C. Landman, MD, clinical fellow in Orthopedic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital, discusses the process of delivering value-based care to patients with cancer.

Zachary Hartman

Latest:

Cost Versus Quality in Different Sites of Cancer Care

More oncology providers have shifted toward consolidation of practices to remain viable. In the last 4 years, 524 private practices have entered into agreements with or have been acquired by hospitals.

Zachary S. Morris, MD, PhD

Latest:

Combinations With RT May Improve Immunotherapy Response

One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.